AbbVie (NYSE: ABBV) is investing in its artificial intelligence (AI) infrastructure through a new partnership with Valkai, a life sciences AI platform designed to help accelerate the pace at which scientific innovation reaches patients.

Through its partnership with Valkai, AbbVie will deploy purpose-built AI capabilities designed to improve efficiency across targeted areas of clinical research, help teams generate insights more quickly and support opportunities to reduce development timelines.